Arabic Arabic English English French French German German

Viewpoint Molecular Targeting(TM) Appoints Frank Morich, M.D., Ph.D. to its Board of Directors

– Dr. Morich is an industry leader with over 35 years of experience in biopharmaceuticals with focus in commercialization, R&D and product development – – Previously served as Chief Commercial Officer of Takeda Pharmaceutical Company, Chief Executive Officer of Takeda Pharmaceutical International, Chief Executive Officer of NOXXON Pharma AG, Chief Executive Officer of Innogenetics N.V., and Head of Global Product Development of Bayer AG Pharmaceutical Division – Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

A comprehensive review of the antiviral potential of algal metabolites.

Next Post

Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy

Related Posts